Experts have advised that even if there are genetic factors such as family history, correcting some lifestyle habits can prevent cancer occurrence by up to 50%. According to the Korean Cancer ...

Scientists are making rapid progress toward a long-awaited goal that could help to reshape cancer care: mRNA cancer vaccines with the potential to significantly boost the immune system's ability to ...

Early detection plays a major role in recovering from cancer. Dr Chawla shares five symptoms that can help people over 50 ...

Starting next year, Louisiana could require health insurance plans to cover prostate cancer screenings starting at age 40, ...

When he started having symptoms, “cancer was the farthest thing from my mind,” he says. How a liver transplant and his dog ...

The latest stats on cancer death rates in the UK offer encouraging news – and further progress against the disease is within ...

This may not apply in your husband’s case, but it’s worth having the conversation. The two meds Goldstein prescribes for men are flibanserin (Addyi), an oral tablet taken d ...

Clinical benefits of the talazoparib and enzalutamide combination extend to patients with both BRCA and non-BRCA homologous recombination repair gene alterations.

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...

Bellmunt Risk Score predicts survival in mCRPC across treatment lines. Learn how this simple tool can guide prognosis and treatment decisions. Read more.

Pfizer reported positive topline results in its phase three study of talazoparib in combination with enzalutamide to treat metastatic hormone-sensitive prostate cancer. The study met its primary ...

Pfizer (PFE) stock is in focus as Xtandi, marketed with Astellas (ALPMF), and cancer drug Talzenna succeed in a Phase 3 trial for prostate cancer. Read more here.